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Abstract
Growing interest in blood-borne microRNAs (miRNAs) as biomarkers has led to the introduction of a number of commercial
kits for isolating small RNAs from plasma/serum. We sought to compare the efficacy of six such kits in isolating miRNAs
from either whole plasma or a plasma-derived ultracentrifugation (UC) fraction from 2 healthy volunteers with some of the
results being validated in 10 additional subjects. To assess the overall yield and concentration of isolated small RNAs, we
measured the levels of one spiked-in and four endogenous miRNAs by quantitative reverse transcription and polymerase
chain reaction (qRT-PCR). We also tested the performance of the Agilent Bioanalyzer small RNA assay with these RNA sam-
ples. Additionally, we tested the effects of hemolysis on measured miRNA levels in whole plasma and in the UC fraction.
Both the efficiency of RNA isolation and the relative levels of specific miRNAs in different samples varied considerably be-
tween the tested extraction methods. Of all kits tested, the QIAGEN miRNeasy kits (Mini and Serum/Plasma kits) and the
Macherey-Nagel NucleoSpin kit produced the highest RNA yields. The QIAGEN Exo kit produced lesser yields than what
could be extracted from the UC fraction using the QIAGEN miRNeasy kits and the Macherey-Nagel NucleoSpin kit.
Bioanalyzer results showed an average correlation of R2¼0.8 with endogenous miRNA qRT-PCR results, for sample concen-
trations >40 pg/ml. The levels of the endogenous miRNAs measured in the two volunteer samples were compared with those
in a larger group of subjects (n¼10) and found to be typical. Our comparison favors the use of the QIAGEN Serum/Plasma kit
and the Macherey-Nagel NucleoSpin kit for plasma miRNA applications. Furthermore, extraction of miRNAs from the UC
fraction results in higher yield than extraction from whole plasma.
Keywords: Biofluid; biomarkers; small RNAs; nucleic acids; purification; optimization; hemolysis
Introduction
Profiling microRNAs (miRNAs) and other small RNAs in biofluids,
e.g., plasma/serum, has been attracting wide interest due to their
potential as minimally invasive biomarkers of various diseases
(e.g., [1–8]). These RNAs are shielded from degradation by several
mechanisms, such as encapsulation in extracellular vesicles
(EVs), among them exosomes [9–11], and binding to ribonucleo-
protein or lipoprotein complexes [12,13]. Furthermore, circulating
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RNAs may serve as a novel mode of signaling between different
tissues and cell types [10, 14–17]. However, circulating RNAs are
present at very low levels compared to those in tissues or cells,
and their accurate detection and quantification is challenging
due to several compounding pre-analytical variables, such as
sample hemolysis, platelet content, storage, and—notably—RNA
isolation method [18–23]. Several commercial small RNA isolation
kits, some of them biofluid specific, have been introduced in re-
cent years, competing in efficacy, affordability, and ease of use.
Here, we sought to compare the efficacy of six such kits (three
from QIAGEN, one from Norgen Biotek, one from Zymo Research,
and one from Macherey-Nagel) in isolating small RNAs from ei-
ther whole plasma or a plasma-derived ultracentrifugation (UC)
fraction from two healthy volunteers, with some of the results
being substantiated in additional 10 subjects. Furthermore, we
sought to quantify the impact of visible hemolysis on the miRNA
content in whole plasma as well as in the UC fraction.
Materials and methods
Blood was collected from three groups of subjects. The work-
flow for the first two groups (kit comparison and miRNA level
validation) is outlined in Fig. 1A. The workflow for the third
group (the hemolysis test) is shown in Fig. 1B.
In the first (kit comparison) group, blood was collected from
a cubital vein into K2EDTA BD Vacutainer tubes from two
healthy Caucasian male volunteers (aged 37 and 60 years) at
rest following an overnight fast. Plasma was immediately iso-
lated by centrifugation at 2500 g at 4C for 10 min and stored
in aliquots at 80C. These samples were used to generate the
data shown in Figs. 2–4B.
In the second (miRNA-level validation) group, stored (80C)
ethylenediaminetetraacetic acid (EDTA) plasma from 10 sub-
jects who participated in the FINE project was used in order to
further validate some of the data obtained from the first group
of subjects described above. The FINE project was a randomized
control trial mainly addressing the interindividual variation in
insulin sensitivity in sedentary male and the metabolic effects
of 3 months of lifestyle intervention by increased physical activ-
ity. The study population consisted of healthy, sedentary
Caucasian males, 20–40 years of age, body mass index (BMI) 25–
30 kg/m2. Further details of the FINE project have been previ-
ously published [24, 25]. The plasma samples used in the cur-
rent study were obtained after an overnight fast before start of
the intervention program. Data from these samples are shown
in Fig. 4C.
In the third (hemolysis test) group, blood was collected from
a cubital vein into K2EDTA BD Vacutainer tubes in quadruple
replicates from each of two healthy Caucasian volunteers (fe-
male and male, aged 55 and 61 years, respectively) at rest fol-
lowing an overnight fast. All four tubes from each donor were
immediately centrifuged at 2500 g at 4C for 10 min. Plasma
from the first tube (Control) in each subject set was stored in ali-
quots at 80C. The second tube (Control recentrifuged) in both
sets was inverted 10 times (to mix plasma and packed cells),
recentrifuged at 2500 g for 15 min and plasma stored in ali-
quots at 80C. Tubes 3 and 4 in both sets were treated identi-
cally (duplicates). Following the first centrifugation, the packed
erythrocytes at the bottom of the tube were partly hemolyzed
by being drawn through a 23G 30-mm-long needle using a 2-ml
syringe and then injected back into the Vacutainer tube, which
was inverted 10 times to mix plasma and partly hemolyzed
cells, recentrifuged at 2500 g for 15 min and plasma stored in
aliquots at 80C. Data from these samples are shown in Fig. 5.
To obtain the UC fraction, 220 ml of plasma were diluted 1:20
with ice-cold PBS containing 1 mM EDTA in 5-ml Eppendorf
tubes and centrifuged at 15 557 g for 1 min at 4C to remove
any larger particles. Four milliliters (corresponding to 200 ml di-
luted plasma) were then transferred to an UC tube and centri-
fuged at 200 000 g for 16–17 h at 2C in a Beckman 70.1 Ti rotor.
The supernatant was discarded, the tube immediately rinsed
with 4 ml of ice-cold phosphate buffered saline (PBS) containing
1 mM EDTA and the tube wall dried with a couple of cotton
swaps. The pellet (UC fraction) was resuspended in 200 ml of
RNase-free water and stored at 80C.
To assess the degree of hemolysis in plasma or UC samples,
free hemoglobin (fHb) concentration was estimated using the
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Figure 1: Graphic summary of workflows. (A) The workflow for the kit compari-
son group (n¼2) and miRNA level validation group (n¼10). (B) The workflow for
the hemolysis test group (n¼2).
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Harboe method [24, 25]. Briefly, 5 ml plasma were diluted 1:11 in
PBS, and absorption at the wavelengths of 380, 415, and 450 nm
was measured in 96-well plate format in a Tecan Infinite M200
Pro spectrophotometer. Free hemoglobin concentration (fCHb, in
milligrams per milliliters) was calculated using the formula
CHb¼ 0.836[2A415 (A380þA450)] [25] The values were pre-
sented in micrograms per milliliters.
Total RNA isolation used the following kits, with the follow-
ing elution volumes of nuclease-free water (according to manu-
facturers’ recommendations):
i. QIAGEN miRNeasy Mini Kit (Cat. 217004), 30 ml
ii. QIAGEN miRNeasy Serum/Plasma kit (Cat. 217184), 14 ml
iii. QIAGEN exoRNeasy Serum/Plasma Starter Kit (Cat. 77023),
14 ml
iv. Norgen Biotek Plasma/Serum RNA Purification Mini Kit (Cat.
55000), 30 ml
v. Zymo Research Direct-zolTM RNA MiniPrep (Cat. R2050),
14 ml
vi. Macherey-Nagel NucleoSpinTM miRNA Plasma kit (Cat.
740981.10), 30 ml
Each kit was used according to the manufacturer’s instruc-
tions, on both whole plasma and plasma-derived UC fractions
from both volunteers, except the QIAGEN exoRNeasy kit which
was used only on whole plasma samples (as it integrates EV iso-
lation). Samples were lyzed in QIAzol lysis reagent (QIAGEN Cat.
79306) (for kits 1–3 and 5) or the respective lysis buffer included
in the kits (for kits 4 and 6) and spiked with 5.6 108 copies of
miRNeasy Serum/Plasma Spike-In Control (C. elegans miR-39
mimic, QIAGEN Cat. 219610) before proceeding with the extrac-
tion. After elution (using the volumes indicated above), samples
were stored at 80C.
Electrophoretic analysis was performed at the Genomics
Center of the Silberman Institute of Life Sciences, Hebrew
University, Jerusalem, Israel, using the Agilent Small RNA kit on
an Agilent 2100 Bioanalyzer.
Reverse transcription (RT) and quantitative PCR (qPCR) for the
Serum/Plasma Spike-In Control were performed using a QIAGEN
miScript PCR Starter Kit (Cat. 218193) and the PCR primers pro-
vided with the spike-in control. RT, primer design, and qPCR for
endogenous miRNAs were performed using SYBR Green chemis-
try and DNA primers as previously described [26, 27]; primers
used are listed in Table 1. qPCR was performed in quadruplicates
on an Applied Biosystems ABI-7900HT Sequence Detection
System equipped with a 384-well block, using iTaq SYBR Green
(BioRad). This qRT-PCR method is highly accurate and reproduc-
ible [26, 27], and was chosen over TaqMan chemistry due to lower
cost and higher convenience. Results were analyzed with SDS 2.3
(Applied Biosystems) and Microsoft Excel. All qRT-PCR and fHb
measurements are included in the Supplementary Data.
Results
QIAGEN and Macherey-Nagel kits provide the best
combination of concentration and quality of small RNAs
To assess the overall yield and concentration of isolated small
RNAs, the concentration of a spike-in control (cel-miR-39) as
well as four endogenous miRNAs present at different levels in
plasma (miR-451a, miR-21-1, miR-30d, and miR-122) was quan-
tified by qRT-PCR. The spike-in control measurements enabled
absolute quantification of the oligo concentration in the iso-
lates, and the percentage of recovery, based on a standard curve
obtained from serial dilutions of the spike-in control oligo (Fig.
R² = 0.994
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Figure 2: qRT-PCR for one spike-in control (cel-miR-39) in plasma samples from
two donors. (A) Standard curve for spike-in control based on four dilutions span-
ning a 1000-fold difference in input copy number. (B) Concentration of spike-in
control, in million copies per microliters. Note log scale. Both QIAGEN Mini and
QIAGEN Serum/Plasma are miRNeasy kits. The QIAGEN Exo kit was not used in
this assay. Black and white circles mark samples from two subjects, respec-
tively. UC fractions processed with Zymo Direct-Zol yielded no quantitative re-
sults. (C) Overall recovery of spike-in control as percentage of input (equal to
5.6108 copies/sample), in samples as in (B), accounting for elution volume.
Black and white circles mark samples from two subjects, respectively.
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2A). Based on spike-in control amplification, the best RNA con-
centration and overall recovery from whole plasma was ob-
tained by the QIAGEN miRNeasy Serum/Plasma kit and the
Norgen kit (Fig. 2B–C). The UC fraction produced the most RNA
(based on spike-in quantification) when processed with the
Macherey-Nagel kit, followed by the QIAGEN Serum/Plasma kit.
The endogenous miRNA measurements showed the highest
levels in the samples processed with the Macherey-Nagel kit
and the QIAGEN miRNeasy Serum/Plasma kit (Fig. 3). The UC
fraction sample, when processed with the Zymo Direct-Zol kit,
failed to produce reliable quantification of the spike-in control
and of any of the endogenous miRNAs; some of the endogenous
miRNAs also failed to produce quantitative results in the whole
plasma samples when processed with this kit. The samples pro-
cessed by the Norgen kit, although showing adequate concen-
tration and recovery of the spike-in control (Fig. 2B–C), failed to
produce robust quantitative results for the endogenous miRNAs
(Fig. 3), pointing toward a possible problem with RNA purity.
Higher recovery of miRNA from the UC fraction than
from whole plasma
Although blood-borne small RNAs are known not to be exclu-
sively carried by EVs, higher levels of all four endogenous
miRNAs were measured in the UC fraction than in whole
plasma, when using both QIAGEN miRNeasy kits and the
Macherey-Nagel NucleoSpin kit (Fig. 3), suggesting a more effi-
cient RNA isolation from these samples. The similarly higher
concentration and recovery of the spike-in control in the UC
samples (Fig. 2B– C) confirmed that more RNA is recovered from
the UC fraction than from whole plasma, probably due to
plasma components that interfere with the binding or elution of
RNA in the column matrix.
QIAGEN Exo kit yields less RNA than can be recovered
by UC
One of our aims was to evaluate the efficacy of the QIAGEN Exo
kit in isolating small RNAs from EVs, as a substitute for the lon-
ger procedure of EV isolation by UC. Although all endogenous
miRNAs tested could be quantified, their levels were generally
lower when using the Exo kit, when compared with the levels
obtained by extracting RNA with the QIAGEN Serum/Plasma kit
from the UC fraction (Fig. 3). These results may be explained by
non-EV carriers (such as high molecular weight lipoprotein
complexes) being retained by UC but not the Exo kit, and are
consistent with previous findings that only a fraction of plasma
total miRNA is associated with EVs[11]. Another possible expla-
nation is lower EV recovery by the Exo kit than by UC.
Electrophoretic separation analysis shows an average
correlation of R250.8 with endogenous miRNA qRT-PCR
results >40pg/ml
The Agilent Bioanalyzer is a commonly used tool for RNA quan-
tification and quality control and utilizes the principle of
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Figure 3: qRT-PCR for four endogenous miRNAs in plasma samples from two do-
nors. (A–D) Relative concentration of four endogenous miRNAs: miR-122 (A),
miR-21-1 (B), miR-30d (C), miR-451a (D). Levels are relative to the average of Ct
values from all samples obtained with the QIAGEN miRNeasy Serum/Plasma kit
plotted on a log scale. Both QIAGEN Mini and QIAGEN Serum/Plasma are
miRNeasy kits. Black and white circles mark samples from two subjects, respec-
tively. Where one or more circles are absent, one or both samples yielded no
quantitative results. However, the miR-21-1 values from the two subjects in the
QIAGEN miRNeasy Serum/Plasma UC and MN Nucleospin columns are close
enough to overlap in the chart.
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electrophoretic separation. The Bioanalyzer small RNA assay is
designed to quantify RNA samples at concentrations exceeding
50 pg/ml, which limits the use of this method in quantifying
biofluid-derived RNA, as previously reported [23]. To evaluate
the performance of the Bioanalyzer with the rather dilute small
RNAs obtained from the plasma samples using the different
kits, several of the RNA samples were subjected to Bioanalyzer
analysis, which returned concentrations in the order of 30–
150 pg/ml (Fig. 4A). The Bioanalyzer concentration values ob-
tained from samples processed with the three different QIAGEN
miRNeasy kits were then compared with qRT-PCR results for
three endogenous miRNAs (miR-122, miR-21-1, and miR-30d), in
the same samples (a total of eight RNA samples). miR-451a was
excluded due to high variance between subjects. qRT-PCR re-
sults, normalized to the different average expression levels for
each miRNA, showed an average correlation of R2¼ 0.8 to
Bioanalyzer results at concentrations exceeding 40 pg/ml
(Fig. 4B), suggesting that the Bioanalyzer is useful at least as a
rough estimate of the amount of RNA extracted from rather
small plasma volumes (200 ml).
The two volunteer samples show typical expression
levels for the endogenous plasmamiRNAs measured
As the different extraction methods were tested on identical
samples, individual variability in miRNA levels could not cause
any bias in method comparison. However, in order to ascertain
that the individual miRNA levels in the samples from the two
volunteers are indeed within the range commonly observed for
these miRNAs, the levels of the same four endogenous plasma
miRNAs (miR-451a, miR-122, miR-21-1, and miR-30d) were also
measured by qRT-PCR in the UC fractions of plasma from a
group of 10 additional volunteers (see “Methods” section). The
resulting Ct values were compared to those obtained from the
two volunteer samples used elsewhere in this study. As shown
in Fig. 4C, the levels of all four endogenous miRNAs in the two
volunteer samples were within the ranges of values of the larger
group, and did not deviate from the group means by more than
three cycles, which was typical of the overall variation within
the larger group (SD values for miR-451a, miR-122, miR-21-1,
and miR-30d were 3.27, 2.15, 2.85, and 3.09, respectively).
miR-451a is highly prevalent in non-hemolyzed plasma
and its UC fraction
miR-451a is abundant in red blood cells (RBCs) [28, 29], which
has led to its use as a marker of hemolysis in plasma-derived
RNA samples. To rule out hemolysis as a source of miR-451a in
our samples, fCHb in input plasma samples was estimated
0
50
100
150
QI
AG
EN
 m
ini
QI
AG
EN
 m
ini
 - 
UC
QI
AG
EN
 se
ru
m
/p
la
sm
a
QI
AG
EN
 se
ru
m
/p
la
sm
a 
- U
C
QI
AG
EN
 E
xo
 ki
t
Zy
m
o 
Di
re
ct
-Z
ol
Zy
m
o 
Di
re
ct
-Z
ol
 - 
UC
N
or
ge
n 
se
ru
m
/p
la
sm
a
N
or
ge
n 
se
ru
m
/p
la
sm
a 
-
 
UC
R
N
A
 c
o
n
ce
n
tr
at
io
n
 (
p
g
/µµ
l)
R² = 0.8053
0
1
2
3
4
20 40 60 80 100 120 140
n
o
rm
al
iz
ed
 m
iR
N
A
 Q
P
C
R
 le
ve
ls
Bioanalyzer RNA concentration
(pg/µl)
miR-451a 122 21 30d
17
19
21
23
25
27
29
31
33
35
37
C
t
A
B
Figure 4: Agilent Bioanalyzer assessment of small RNA concentration and yield
from plasma samples. (A) Small RNA concentrations obtained with the kits indi-
cated, quantified using Bioanalyzer hardware and software. Both QIAGEN Mini
and QIAGEN Serum/Plasma are miRNeasy kits. Black and white circles mark
samples from two subjects, respectively. (B) Correlation between average RNA
measurements as in A and average qRT-PCR results (as in Fig. 3) for three endog-
enous miRNAs (miR-122, miR-21-1, and miR-30d), in samples processed with
the following QIAGEN miRNeasy kits: Mini and Serum/Plasma. miR-451a was ex-
cluded due to high variance between subjects. Mean6SD from three miRNAs.
Trend line (dashed)—least squares linear. (C) Comparison of the expression lev-
els (indicated by Ct values) of four endogenous miRNAs (miR-122, miR-21-1,
miR-30d, and miR-451a) between the UC fractions of the same two volunteer
samples used elsewhere in this study, and an independent group of 10 addi-
tional subject samples (characterized in “Methods” section). All samples were
processed using UC and the QIAGEN Serum/Plasma miRNeasy kit. Values from
volunteers 1 and 2 are marked by larger black and gray circles, respectively.
White circles mark values from the 10 additional subjects. Horizontal black bars
indicate the 10-subject group means.
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using the Harboe method [30, 31]. The resulting fHb estimates
were 5 mg/ml for Volunteer 1 and <1 mg/ml for Volunteer 2.
Thus, our data show that this miRNA is highly prevalent in the
UC fraction of plasma as well as whole plasma prepared under
well-controlled conditions with practically undetectable he-
molysis. Although miR-451a levels were lowest in the samples
processed with the Exo kit (Fig. 3D), they were still high
compared to other miRNAs. These results suggest that miR-
451a is not merely an indicator of hemolysis or RBC contami-
nation, but rather an abundant miRNA in several compart-
ments of human blood. RNA-seq analysis (data not shown)
also indicates that miR-451a is consistently one of the three
most abundant miRNAs in plasma, and specifically in the UC
fraction.
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Figure 5: Assessment of the effects of hemolysis on miRNA levels in plasma and UC fraction. (A) Photograph of the sample tubes after initial centrifugation to separate
cells from plasma. The numbers 3 and 4 refer to two volunteers who contributed the samples. For non-hemolyzed samples, the suffixes A and B refer to the two meth-
ods of plasma preparation mentioned in “Methods” section (without and with mixing and recentrifugation, respectively). For hemolyzed samples (markedþLys), the
suffixes A and B indicate duplicates. (B) fHb estimate in plasma samples as shown in (A), using Harboe’s spectroscopic method (see “Methods” section). MeanþSD
from duplicate measurements. (C–F) Relative concentration of four endogenous miRNAs: miR-122 (C), miR-21-1 (D), miR-30d (E), miR-451a (F) in RNA isolated from
plasma samples as in (A) and their respective UC fractions. Levels are relative to the average of Ct values for all four miRNAs for the given sample, plotted on a log scale.
Black and white circles mark whole plasma or UC fraction, respectively.
Table 1: QPCR primers used
Gene Forward primer Reverse Primer
miR-30d AGTGTAAACATCCCCGACT TCCAGTTTTTTTTTTTTTTTCTTCCA
miR-21-1 GCAGTAGCTTATCAGACTGATG GGTCCAGTTTTTTTTTTTTTTTCAAC
miR-122 AGTGGAGTGTGACAATGGT CCAGTTTTTTTTTTTTTTTCAAACACC
miR-451a CAGAAACCGTTACCATTACTGA GGTCCAGTTTTTTTTTTTTTTTAACTC
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Hemolysis dramatically affects the levels of miR-451a
but not other tested miRNAs
To test the effect of hemolysis on miRNA levels, a new set of
plasma samples was collected, with some of them undergoing
controlled hemolysis (see “Methods” section and Fig. 1B). The
hemolyzed samples had a clearly visible reddish tint (Fig. 5A).
These samples were processed into RNA using the QIAGEN
miRNeasy Serum/Plasma kit and the levels of the same four en-
dogenous plasma miRNAs (miR-451a, miR-122, miR-21-1, and
miR-30d) were measured by qRT-PCR. In parallel, aliquots of the
whole plasma were used for fHb concentration estimates using
the Harboe method. The hemolyzed samples produced fHb val-
ues in the range of 40–100 mg/ml, while the non-hemolyzed sam-
ples contained <5 mg/ml fHb (Fig. 5B). Hemolysis had a minor
effect on the measured levels of three of the endogenous
miRNAs, with miR-122 showing somewhat lower levels (Fig. 5C),
miR-21 appearing practically unaffected (Fig. 5D), and miR-30d
showing slightly higher levels in the hemolyzed samples
(Fig. 5E) compared to non-hemolyzed controls. The exception
was miR-451a, which was elevated approximately 10-fold in the
hemolyzed samples compared to controls (Fig. 5F; note the loga-
rithmic scale). This result is in line with the known high con-
centration of miR-451a in RBCs.
UC does not negate the effects of hemolysis on miRNA
levels
We wished to test whether UC can separate the heavier miRNA
carriers (such as vesicles) from the released contents of
hemolyzed RBCs, and thus negate the effects of hemolysis on
endogenous miRNA levels. To address this question, UC frac-
tions from the same sample set as described above were pro-
cessed into RNA using the QIAGEN miRNeasy Serum/Plasma kit
and the levels of the same four endogenous plasma miRNAs
(miR-451a, miR-122, miR-21-1, and miR-30d) were measured by
qRT-PCR. For all four miRNAs, the measured levels were similar
between the UC fractions and their respective whole plasma
samples, including the hemolyzed ones (Fig. 5C–F). In particular,
UC failed to decrease the high levels of miR-451a detected in the
hemolyzed samples (Fig. 5F), indicating that most of the miR-
451a molecules released from hemolyzed RBCs are bound to
complexes, which are massive enough to be pelleted by UC, at
least in our protocol.
Discussion
Growing interest in biofluid—contained small noncoding RNAs
underscores the need for optimized isolation and quantification
protocols. This need has led to the rapid development of com-
mercial reagents, as well as to widespread “trial and error” test-
ing for appropriate controls and workflows. Our present
comparison suggests that the QIAGEN miRNeasy Serum/Plasma
kit and the Macherey-Nagel NucleoSpinTM miRNA Plasma kit
produce the best results in terms of miRNA yields and purity,
among all kits tested, in agreement with others [32].
Additionally, our results indicate that UC can improve miRNA
yields with these kits. This finding suggests that whole plasma
may contain substances that somewhat decrease the efficacy of
RNA isolation, and also that the bulk of plasma miRNAs is con-
tained in vesicles or bound to complexes that are massive
enough to be pelleted by UC. Supporting this notion, no robust
miRNA expression was detected in plasma depleted from its UC
fraction (data not shown). However, UC (at least in our protocol)
did not remove miRNA-containing material that was released
from lyzed RBCs in hemolyzed samples.
miR-451a, which is among the most prevalent miRNAs in
plasma, was previously suggested as both a hemolysis marker
and a normalizer for qRT-PCR measurements in non-hemolyzed
samples [28]. Although our results confirm its high levels in
non-hemolyzed samples, its even higher levels in RBCs make it
extremely sensitive to even a very minor degree of hemolysis,
perhaps even such as to be undetectable by spectroscopy. This
is in agreement with previous findings [29] and underscores the
need for attention to individual samples and thorough quality
control in the choice of normalizers. Elevated miR-451a levels
due to hemolysis, when this miRNA is used as a normalizer, will
lead to a perceived decrease in the levels of most other miRNAs,
and can thus be identified at the stage of data analysis. In gen-
eral, our and others’ experience favors the use of global normal-
ization, or at least using the average of multiple normalizers, for
most qRT-PCR experiments.
Our current comparison also exemplifies the different sour-
ces of variation that gets introduced into the final result of small
RNA quantification, whether by qRT-PCR or other methods
(such as RNA-seq). Some of these variation sources, such as the
difference in efficiency between isolation kits, are easily con-
trolled by the experimental design; others have to be accounted
for at the stage of data analysis. These include differences in
plasma processing and preparation [33, 34], random differences
in RNA purification efficiency between samples when using the
same kit and protocol; differences between RT reactions and
qPCR runs performed on the same sample at different times,
etc. Furthermore, the plasma levels of many miRNAs differ be-
tween subjects (exemplified in Fig. 4C), and these differences
are often dramatic when compared to the variation of expres-
sion in tissues or cells. Hence, study-specific optimization of
normalization controls is often necessary.
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